Ouast U, Bray K M, Baumlin Y, Andres H, Manley P W
Department of Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.
Jpn J Pharmacol. 1992;58 Suppl 2:226P-231P.
The K+ channel openers (KCOs) form a structurally heterogeneous group of compounds which relax smooth muscle by opening K+ channels in the plasmalemma. At present it is not known whether these drugs open the same K+ channel in smooth muscle and, if so, whether they bind to the same site of this channel. To address these questions we present the first binding study with KCOs in a smooth muscle preparation. In intact rat aortic strips, the novel tritiated KCO, 3H-P1075 (N-cyano-N'-(1,1-dimethyl[2,2,3,3(3)H]propyl)-N"-3-pyridylguanidine++ +), a potent pinacidil analogue, showed saturable specific binding of high affinity (KD = 6 +/- 1 nM, Bmax = 23 +/- 3 fmol/mg tissue wet weight). Specific binding of 3H-P1075 was inhibited stereospecifically by representatives from all major families of K+ channel openers, with a rank order of potency that correlated well with the potencies for vasorelaxation in rat aorta. The sulfonylurea glibenclamide, a relatively specific blocker of ATP-sensitive K+ channels and an inhibitor of the effects of KCOs, also inhibited 3H-P1075 binding and increased the rate of dissociation of 3H-P1075 from the tissue in a concentration-dependent manner. Lowering temperature (from 37 degrees C to 2 degrees C) and decreasing intracellular ATP levels by metabolic poisoning, diminished specific 3H-P1075 binding by reducing Bmax. However, depolarization (KCl = 55 mM) or lowering pH from 7.4 to 6.0 did not influence binding. The data demonstrate the existence of a specific binding site for the KCO 3H-P10756 in rat isolated aorta, which seems to be of functional relevance.(ABSTRACT TRUNCATED AT 250 WORDS)
钾通道开放剂(KCOs)构成了一类结构异质的化合物,它们通过打开质膜中的钾通道来舒张平滑肌。目前尚不清楚这些药物在平滑肌中是否打开相同的钾通道,如果是,它们是否与该通道的同一部位结合。为了解决这些问题,我们在平滑肌制剂中进行了首次关于KCOs的结合研究。在完整的大鼠主动脉条中,新型的氚标记KCO,3H-P1075(N-氰基-N'-(1,1-二甲基[2,2,3,3(3)H]丙基)-N"-3-吡啶基胍++ +),一种有效的匹那地尔类似物,表现出高亲和力的可饱和特异性结合(KD = 6±1 nM,Bmax = 23±3 fmol/mg组织湿重)。3H-P1075的特异性结合被所有主要钾通道开放剂家族的代表立体特异性抑制,其效力顺序与大鼠主动脉中血管舒张的效力密切相关。磺酰脲类格列本脲,一种相对特异性的ATP敏感性钾通道阻滞剂和KCOs作用的抑制剂,也抑制3H-P1075结合,并以浓度依赖性方式增加3H-P1075从组织中的解离速率。降低温度(从37℃降至2℃)和通过代谢中毒降低细胞内ATP水平,通过降低Bmax减少了特异性3H-P1075结合。然而,去极化(KCl = 55 mM)或将pH从7.4降至6.0并不影响结合。数据表明在大鼠离体主动脉中存在KCO 3H-P10756的特异性结合位点,这似乎具有功能相关性。(摘要截断于250字)